Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-04

Study Completion Date

2024-01-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot early phase I trial studies the side effects of temozolomide, radiation therapy, and tumor treating fields therapy using Novo tumor treatment fields (TTF)-200A device in participants with glioblastoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. NovoTTF-200A device is a portable device that produces alternating electrical fields that may disrupt growth of cancer cells. Giving temozolomide, radiation therapy, and tumor treating fields therapy using NovoTTF-200A device may work better in treating participants with glioblastoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

NCT00379470

Recurrent Glioblastoma Multiforme

COMPLETED PHASE3

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

NCT04474353

Glioblastoma Newly Diagnosed Glioblastoma

COMPLETED PHASE1

Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM

NCT00548938

Glioblastoma Multiforme High-Grade Glioma

TERMINATED PHASE2

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

NCT03251027

Glioblastoma WHO Grade II Glioma WHO Grade III Glioma

ACTIVE_NOT_RECRUITING NA

Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

NCT01478854

Glioblastoma Multiforme

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To evaluate the safety and toxicity of combination chemoradiotherapy with NovoTTF-200A device (Optune) treatment in newly diagnosed glioblastoma.

SECONDARY OBJECTIVES:

I. To determine the median progression-free survival of patients with newly diagnosed glioblastoma treated with radiotherapy with concurrent and adjuvant temozolomide plus Optune.

II. To evaluate the median overall survival, 1-year overall survival, and event-free survival.

III. Collect tumor O(6)-Methylguanine-DNA-methyltransferase (MGMT) methylation status and isocitrate dehydrogenase (IDH) mutation status.

IV. To evaluate the level of circulating tumor deoxyribonucleic acid (DNA) in glioblastoma patient serum during treatment.

V. To evaluate the quality of life of patients treated with radiotherapy with concurrent and adjuvant temozolomide plus Optune.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (temozolomide, radiation, NovoTTF-200A device)

Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Temozolomide

Intervention Type DRUG

Given PO

Radiation Therapy

Intervention Type RADIATION

Undergo radiation therapy

NovoTTF-200A Device

Intervention Type DEVICE

Undergo tumor treatment fields therapy using NovoTTF-200A device

Tumor Treating Fields Therapy

Intervention Type PROCEDURE

Undergo tumor treatment fields therapy using NovoTTF-200A device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temozolomide

Given PO

Intervention Type DRUG

Radiation Therapy

Undergo radiation therapy

Intervention Type RADIATION

NovoTTF-200A Device

Undergo tumor treatment fields therapy using NovoTTF-200A device

Intervention Type DEVICE

Tumor Treating Fields Therapy

Undergo tumor treatment fields therapy using NovoTTF-200A device

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

362856 Temcad Temodal Methazolastone Temodar Cancer Radiotherapy Irradiate RT Optune Alternating Electric Field Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma
* Karnofsky performance status (KPS) ≥ 60
* Patients must have recovered from the effects of surgery per treating physician's judgment; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatment
* Absolute neutrophil count (ANC) ≥ 1,000 cells/mm\^3
* Platelets ≥ 100,000 cells/mm\^3
* Hemoglobin ≥ 9.0 g/dl
* Creatinine clearance \> 30 mL/min
* Bilirubin \< 2.0 mg/dL
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 3 x upper limit of normal range
* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide
* Is able to have magnetic resonance imaging (MRI) with contrast of the brain
* All subjects must be able to comprehend and sign a written informed consent document. If the subject can comprehend the informed consent but is unable to sign, a LAR may sign the written informed consent document.

Exclusion Criteria

* Infratentorial disease (defined as glioblastoma \[GBM\] derived from cerebellum or brainstem)
* Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias
* A skull defect (such as, missing bone with no replacement)
* Women of childbearing potential who are pregnant or breastfeeding
* Evidence of increased intracranial pressure (midline shift \> 5 mm, clinically significant papilledema)
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study, in the opinion of the investigator
* Prior radiation treatment to the brain
* Prior treatment with temozolomide
* Known hypersensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes
* Known active collagen vascular disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No